What can you tell us about recent clinical studies involving remote pressure-sensing technologies in aortic aneurysm therapy?
The APEX trial showed the safety and effectiveness of remote pressure-sensing devices in the determination of acute aneurysm exclusion, and the PRICELESS study is being initiated to look at long-term efficacy of the pressure-sensing technology. The PRICELESS study has been designed, and there are a number of sites that are going to be involved. Remote pressure-sensor technology is currently only FDA approved for acute exclusion, but we are in the process of getting approval through the Institutional Review Board to begin participating in the study at Emory. What is the potential for pressure-sensing technology to teach us about aneurysmal disease pathology after therapy, in addition to monitoring for sac pressure and regression? If an aneurysm is well excluded and shrinking, then the operator has performed an effective repair. The bigger issue is for the patients with type II endoleaks; we do not yet understand which aneurysms are going to expand and which will remain stable, and we se
